HIV pre-exposure prophylaxis (PrEP) is a daily pill that prevents HIV acquisition. In March 2018, New Zealand became one of the first countries in the world to publicly fund PrEP for individuals at high risk. PrEP promises significantly improved HIV control but is unfamiliar to most health practitioners here, compromising its potential. In this article we review the rationale for PrEP and identify barriers to rapid implementation. The latter include: consumer and health practitioner awareness; acceptability; scale-up targets; prescribing and pharmacy bottlenecks; service capacity to manage follow-up; primary care training; monitoring systems for uptake and quality; equity; eligibility; risk compensation and policy. Many of these areas are ripe for research and innovation. By addressing these obstacles we can realise the potential of PrEP and move closer to ending HIV in Aotearoa/New Zealand.
Download full-text PDF |
Source |
---|
BMC Health Serv Res
January 2025
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, Bilthoven, 3720 BA, The Netherlands.
HIV self-sampling and -testing (HIVSS/ST) reduces testing barriers and potentially reaches populations who may not test otherwise. In the Netherlands, at-home HIV tests became commercially available around 2016, but data on user experiences are limited. This study aimed to explore characteristics of users and their experiences with HIVSS/ST.
View Article and Find Full Text PDFViruses
January 2025
Centre for Virus Research, The Westmead Institute for Medical Research, Westmead 2145, Australia.
Anogenital inflammation is a critical risk factor for HIV acquisition. The primary preventative HIV intervention, pre-exposure prophylaxis (PrEP), is ineffective in blocking transmission in anogenital inflammation. Pre-existing sexually transmitted diseases (STIs) and anogenital microbiota dysbiosis are the leading causes of inflammation, where inflammation is extensive and often asymptomatic and undiagnosed.
View Article and Find Full Text PDFAppl Clin Inform
January 2025
Department of Internal Medicine, Division of Infectious Diseases and Geographic Medicine, The University of Texas Southwestern Medical Center, Dallas, United States.
Background: Global efforts aimed at ending human immunodeficiency virus (HIV) incidence have adapted and evolved since the turn of the century. The utilization of machine learning incorporated into an electronic health record (EHR) can be refined into prediction models that identify when an individual is at greater HIV infection risk. This can create a novel and innovative approach to identifying patients eligible for preventative therapy.
View Article and Find Full Text PDFPLoS One
January 2025
Division of Global HIV & TB, US Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Background: In Uganda, adolescent girls', and young women's (AGYW-15-24 years) current HIV prevalence is fourfold compared with their male counterparts due to compounded social, economic, and environmental factors. Using the Protective Motivation Theory (PMT), we explored HIV-acquisition risk sources and perceived protective factors from AGYW and caregivers' perspective.
Materials And Methods: During 2018, we conducted a qualitative study guided by PMT to explore factors influencing HIV acquisition among AGYW.
AIDS Behav
January 2025
Department of Human Development and Family Sciences, University of Connecticut, Storrs, CT, USA.
Healthy aging is an important area of research across many populations, but less work has focused on this area among sexual and gender diverse individuals relative to the general population. On the whole, it is known that as the U.S.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!